Novartis terminates collaboration agreement with BioArctic on a new treatment
FROM THE WIRE · FINANCE.YAHOO.COM
STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishTermination of a deal with a large pharma partner can weigh on sentiment, though BioArctic keeps the upfront payment.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Novartis notified BioArctic that it is terminating the collaboration agreement entered into in August 2025.
- 02The decision results from Novartis discontinuing the program, unrelated to the BrainTransporter technology.
- 03BioArctic will retain the full USD 30 million upfront payment and recognize the remaining portion as 2026 revenue.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets